Urology Update: For Primary Care and Advanced Practice Providers (2017)
We invite you to attend this complimentary CME activity (pre-registration required) with the latest research from the experts on the urologic issues most relevant to front-line patient care. The purpose of this program is to provide primary healthcare professionals, advanced practice providers and allied healthcare professionals with practical knowledge that will allow you to respond effectively to the needs of patients with urologic diseases.
This free, half-day course will enhance your knowledge to help improve patient care in the following areas while focusing on the review of AUA Guidelines:
- Prostate Cancer
- Bladder Cancer
- Renal Cancer
- Stress Urinary Incontinence
- Overactive Bladder
- Bladder Pain Syndrome/Interstitial Cystitis
- Family practitioners
- Nurse practitioners
- Physician assistants
- Allied healthcare professionals
- Other primary healthcare professionals
After attending this course, participants will be able to:
- Effectively utilize the AUA Guidelines.
- Discuss the epidemiology and genetic factors.
- Describe the PSA controversy and AUA guideline recommendations.
- Identify the diagnostic methods of staging and grading of prostate cancer.
- Review the treatment options for localized and advanced cancer.
- Discuss the epidemiology and risk factors.
- Identify the diagnostic methods of staging and grading of bladder cancer.
- Describe the use of Intravesical therapy for non-invasive bladder cancer.
- Compare treatment options for muscle invasive bladder cancer – surgical, radiotherapy, and chemotherapy.
- Discuss the epidemiology and genetic risk factors.
- Review the treatment options for renal cell cancer and transitional cell kidney cancer.
- Discuss new and exciting chemotherapeutic treatment options for advanced renal cell carcinoma.
Stress Urinary Incontinence
- Explain the etiology of stress incontinence in women and associated comorbidities.
- Outline appropriate evaluation for stress incontinence.
- Review current treatment options available for stress incontinence and when to refer.
- Outline a stepwise evaluation for the patient with overactive bladder.
- Describe management options for OAB including pharmacotherapy, Botox and Neuromodulation according to AUA/SUFU guidelines.
- Determine when it is appropriate to refer to a specialist.
- Identify common causes and comorbidities associated with nocturia.
- Describe the baseline evaluation and appropriate testing for initial work up of nocturia.
- Outline various treatment options for nocturia including when to initiate referral to an appropriate specialist.
Bladder Pain Syndrome/Interstitial Cystitis – Females
- Discuss the diagnosis and treatment of interstitial cystitis.
- Identify the associated organ systems involved with chronic pelvic pain.
6:30 - 7:30 a.m. Registration
7:30 - 7:35 a.m. Introduction - Howard N. Winfield, MD
7:35 - 7:50 a.m. Pre-test - Howard N. Winfield, MD
Session I: Oncology
7:50 – 8:30 a.m. Prostate Cancer – Why all the Controversy? - Howard N. Winfield, MD
8:30 – 9:00 a.m. Bladder Cancer – the Dangerous Lurking Malignancy - Michael A. O’Donnell, MD
9:00 – 9:25 a.m. Renal Cancer – the Internist’s Disease in the Era of CT Scanning - David S. Wang, MD
9:25 – 9:40 a.m. Panel Discussion: When to Refer?
9:40 – 9:45 a.m. Session I Post-test
9:45 – 10:00 a.m. Break
Session II: Voiding Dysfunction
10:00 – 10:20 a.m. Stress Urinary Incontinence – Evaluation and Management Strategies - Matthew R. Thom, MD, FACS
10:20- 11:00 a.m. Overactive Bladder – Making and Setting Expectations for Treatment Selection - Matthew R. Thom, MD, FACS
11:00 – 11:20 a.m. Nocturia – Important Considerations and Management Strategies - Sandip Prasan Vasavada, MD
11:20 – 11:50 a.m. Bladder Pain Syndrome/Interstitial Cystitis – Females - Sandip Prasan Vasavada, MD
11:50 a.m. – 12:05 p.m. Panel Discussion: When to Refer?
12:05 – 12:15 p.m. Session II Post-test/Wrap-up - Howard N. Winfield, MD
12:15 p.m. Adjourn
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
The AUA designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This live activity, Urology Update 2017: For Primary Care and Advanced Practice Providers, with a beginning date of 5/13/2017, has been reviewed and is acceptable for up to 4.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation for Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 4.5 hours of Category I credit for completing this program.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 4.50 AMA PRA Category 1 Credit™
- 4.50 Non-Physician Participation
- 4.50 AAFP Prescribed